Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KYMR NASDAQ:SANA NASDAQ:SRRK NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYMRKymera Therapeutics$59.86-4.8%$48.06$19.44▼$63.96$4.29B2.26752,771 shs431,523 shsSANASana Biotechnology$5.27-11.1%$3.47$1.26▼$7.30$1.26B1.915.74 million shs12.79 million shsSRRKScholar Rock$29.37-9.3%$33.86$22.71▼$46.98$2.82B0.421.56 million shs3.16 million shsVKTXViking Therapeutics$34.51-1.7%$29.33$18.92▼$81.73$3.88B0.644.86 million shs3.87 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYMRKymera Therapeutics+7.95%+11.72%+33.02%+35.69%+40.38%SANASana Biotechnology+33.03%+30.68%+83.28%+33.03%+43.00%SRRKScholar Rock+1.57%-16.26%-3.77%-24.41%+13.52%VKTXViking Therapeutics+6.26%+8.50%+45.85%+9.51%-46.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYMRKymera Therapeutics$59.86-4.8%$48.06$19.44▼$63.96$4.29B2.26752,771 shs431,523 shsSANASana Biotechnology$5.27-11.1%$3.47$1.26▼$7.30$1.26B1.915.74 million shs12.79 million shsSRRKScholar Rock$29.37-9.3%$33.86$22.71▼$46.98$2.82B0.421.56 million shs3.16 million shsVKTXViking Therapeutics$34.51-1.7%$29.33$18.92▼$81.73$3.88B0.644.86 million shs3.87 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYMRKymera Therapeutics+7.95%+11.72%+33.02%+35.69%+40.38%SANASana Biotechnology+33.03%+30.68%+83.28%+33.03%+43.00%SRRKScholar Rock+1.57%-16.26%-3.77%-24.41%+13.52%VKTXViking Therapeutics+6.26%+8.50%+45.85%+9.51%-46.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKYMRKymera Therapeutics 2.95Moderate Buy$61.26-1.26% DownsideSANASana Biotechnology 2.75Moderate Buy$7.5036.24% UpsideSRRKScholar Rock 3.07Buy$48.6065.08% UpsideVKTXViking Therapeutics 2.86Moderate Buy$86.42147.93% UpsideCurrent Analyst Ratings BreakdownLatest SANA, KYMR, SRRK, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/9/2025SRRKScholar RockBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$53.0010/8/2025KYMRKymera TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SANASana BiotechnologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SRRKScholar RockWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VKTXViking TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/1/2025KYMRKymera TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$53.00 ➝ $63.009/30/2025KYMRKymera TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $68.009/29/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.009/27/2025KYMRKymera TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SANASana BiotechnologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SRRKScholar RockWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKYMRKymera Therapeutics$44.71M99.22N/AN/A$12.90 per share4.81SANASana BiotechnologyN/AN/AN/AN/A$1.12 per shareN/ASRRKScholar RockN/AN/AN/AN/A$3.94 per shareN/AVKTXViking TherapeuticsN/AN/AN/AN/A$7.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKYMRKymera Therapeutics-$223.86M-$3.47N/AN/AN/A-616.03%-31.60%-27.12%10/30/2025 (Estimated)SANASana Biotechnology-$266.76M-$1.06N/AN/AN/AN/A-91.96%-43.07%11/14/2025 (Estimated)SRRKScholar Rock-$246.29M-$2.91N/AN/AN/AN/A-127.11%-90.09%11/11/2025 (Estimated)VKTXViking Therapeutics-$109.96M-$1.53N/AN/AN/AN/A-19.98%-19.38%10/22/2025 (Estimated)Latest SANA, KYMR, SRRK, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025SRRKScholar Rock-$0.88N/AN/AN/A$0.05 millionN/A10/30/2025Q3 2025KYMRKymera Therapeutics-$0.73N/AN/AN/AN/AN/A10/22/2025Q3 2025VKTXViking Therapeutics-$0.71N/AN/AN/AN/AN/A8/11/2025Q2 2025KYMRKymera Therapeutics-$0.83-$0.95-$0.12-$0.95$17.37 million$11.48 million8/11/2025Q2 2025SANASana Biotechnology-$0.20-$0.16+$0.04-$0.39N/AN/A8/6/2025Q2 2025SRRKScholar Rock-$0.66-$0.98-$0.32-$0.98$0.11 millionN/A7/23/2025Q2 2025VKTXViking Therapeutics-$0.44-$0.58-$0.14-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKYMRKymera TherapeuticsN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKYMRKymera TherapeuticsN/A8.328.32SANASana BiotechnologyN/A2.472.47SRRKScholar Rock0.216.336.33VKTXViking TherapeuticsN/A25.8625.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKYMRKymera TherapeuticsN/ASANASana Biotechnology88.23%SRRKScholar Rock91.08%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipKYMRKymera Therapeutics16.01%SANASana Biotechnology30.10%SRRKScholar Rock13.30%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKYMRKymera Therapeutics17071.50 million60.05 millionOptionableSANASana Biotechnology380237.81 million166.23 millionOptionableSRRKScholar Rock14096.13 million83.34 millionOptionableVKTXViking Therapeutics20112.45 million107.84 millionOptionableSANA, KYMR, SRRK, and VKTX HeadlinesRecent News About These CompaniesRFG Advisory LLC Acquires 25,387 Shares of Viking Therapeutics, Inc. $VKTXOctober 16 at 4:48 AM | marketbeat.comViking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025October 15 at 4:05 PM | prnewswire.comViking Therapeutics (VKTX) Projected to Post Earnings on WednesdayOctober 15 at 2:35 AM | marketbeat.comViking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to NoteOctober 14 at 6:51 PM | zacks.comViking Therapeutics (NASDAQ:VKTX) Shares Down 2.5% - Should You Sell?October 14 at 5:40 PM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Up 1% - What's Next?October 13 at 5:57 PM | marketbeat.comIFP Advisors Inc Acquires 10,048 Shares of Viking Therapeutics, Inc. $VKTXOctober 13 at 6:08 AM | marketbeat.comM&A Speculation Fuels Volatility in Viking Therapeutics SharesOctober 12, 2025 | aktiencheck.deAViking Therapeutics, Inc. $VKTX Shares Acquired by Blair William & Co. ILOctober 12, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Down 4.1% - What's Next?October 10, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Purchases New Stake in Viking Therapeutics, Inc. $VKTXOctober 10, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Price Up 8.1% - Should You Buy?October 10, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by BrokeragesOctober 9, 2025 | americanbankingnews.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Rating of "Moderate Buy" by BrokeragesOctober 9, 2025 | marketbeat.comViking Therapeutics' (VKTX) Sell (D-) Rating Reaffirmed at Weiss RatingsOctober 8, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Up 2.6% - Here's WhyOctober 8, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Down 2.3% - Here's WhyOctober 7, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Up 8.6% - Here's What HappenedOctober 6, 2025 | marketbeat.comWhy Viking Therapeutics (VKTX) Is Up 15.1% After Acquisition Buzz and Analyst Focus on Its PipelineOctober 6, 2025 | finance.yahoo.comViking Therapeutics:Â A Speculative BuyOctober 4, 2025 | seekingalpha.comViking Therapeutics (NASDAQ:VKTX) Stock Price Up 6.6% - What's Next?October 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSANA, KYMR, SRRK, and VKTX Company DescriptionsKymera Therapeutics NASDAQ:KYMR$59.86 -3.03 (-4.82%) As of 03:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Sana Biotechnology NASDAQ:SANA$5.26 -0.66 (-11.06%) As of 03:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.Scholar Rock NASDAQ:SRRK$29.37 -3.03 (-9.35%) As of 03:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Viking Therapeutics NASDAQ:VKTX$34.51 -0.61 (-1.75%) As of 03:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
